Edit
Cour Pharmaceuticals Development Company, Inc.
https://courpharma.com/Last activity: 22.09.2024
Active
We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.
Location: United States, Illinois, Skokie
Employees: 11-50
Total raised: $135M
Founded date: 2015
Investors 3
| Date | Name | Website |
| 08.02.2024 | Lumira Ven... | lumiravent... |
| 22.09.2024 | T1D Fund | t1dfund.or... |
| - | Alpha Wave... | alphawaveg... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.02.2024 | Series A | $105M | Lumira Ven... |
| 07.09.2022 | - | $30M | - |
Mentions in press and media 9
| Date | Title | Description |
| 30.01.2024 | Cour Pharmaceuticals lands $105 million for next phase of clinical trials | - |
| 30.01.2024 | Cour Pharmaceuticals Closes Approximately $105M Series A Funding | Cour Pharmaceuticals, a Chicago, IL-based clinical-stage biotechnology company, raised approximately $105M Series A funding. The round was led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (a... |
| 30.01.2024 | COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures | CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) — COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease modifying therapies designed to induce antigen-specific tolerance for immune-mediated... |
| 30.01.2024 | Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million | John Puisis was dubious when he first heard about the autoimmune science being developed by a coalition of scientists from Northwestern University and the University of Sydney. The group was developing a sort of Trojan horse that it hoped c... |
| 07.09.2022 | Cour Pharmaceuticals Raises $30M in Funding | Cour Pharmaceuticals, a Chicago, IL-based clinical-stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders, raised $30... |
| - | Cour Pharmaceuticals Development | “Reprogramming the Immune System About COUR Who We Are COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of... |
| - | Cour Pharmaceuticals Development | “COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...” |
| - | Manage your consent preferences Cour Pharmaceuticals lands $105 million for next phase of clinical trials | - |
| - | Cour Pharmaceuticals Development | “Reprogramming the immune system. Restoring lives.At COUR, we develop targeted therapies that incite calm within the immune system and help restore the healt ...” |